-+ 0.00%
-+ 0.00%
-+ 0.00%
CytomX Earns $5 Million Milestone Payment in Regeneron Cancer Drug Collaboration
Share
Listen to the news
CytomX Earns $5 Million Milestone Payment in Regeneron Cancer Drug Collaboration
  • CytomX Therapeutics achieved a preclinical milestone in its Regeneron collaboration, triggering a $5 million payment.
  • The milestone marks progress toward clinical development of conditionally activated cancer therapies designed to limit activity outside tumors.
  • The collaboration began in 2022 and expanded in June 2026, combining therapeutic masking technology with Regeneron's bispecific antibody platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611171615PRIMZONEFULLFEED9879830) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending